LAUSR

Diabetes has turned out to be an epidemic in the recent years all over the world, and today it has become a burden on the healthcare system. Over the years, with technological advancements, different classes of antidiabetic medications have emerged, like sulfonylureas, biguanides, alpha‐glucosidase inhibitors, and thiazolidinediones, but these are often loaded with serious aftermaths like hypoglycemia, weight gain, cardiovascular and renal issues. Dipeptidyl peptidase‐4 (DPP‐4) inhibition is an exciting and new approach in the treatment of type‐2 diabetes. DPP‐4 inhibitors or “gliptins” are weight neutral, pose lesser risk of hypoglycemia, and provide a long‐term post‐meal glycemic control. In this review, an attempt has been made to investigate novel potential compounds that can be added to the existing list of anti‐diabetic drugs.